These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 8183926)

  • 1. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins.
    Ishibashi S; Herz J; Maeda N; Goldstein JL; Brown MS
    Proc Natl Acad Sci U S A; 1994 May; 91(10):4431-5. PubMed ID: 8183926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice.
    Véniant MM; Withycombe S; Young SG
    Arterioscler Thromb Vasc Biol; 2001 Oct; 21(10):1567-70. PubMed ID: 11597927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lecithin:cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice.
    Furbee JW; Sawyer JK; Parks JS
    J Biol Chem; 2002 Feb; 277(5):3511-9. PubMed ID: 11719520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotype interaction of apobec-1 and CETP, LDLR, and apoE gene expression in mice: role of apoB mRNA editing in lipoprotein phenotype expression.
    Nakamuta M; Taniguchi S; Ishida BY; Kobayashi K; Chan L
    Arterioscler Thromb Vasc Biol; 1998 May; 18(5):747-55. PubMed ID: 9598833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of low density lipoprotein receptor eliminates apolipoprotein B100-containing lipoproteins from circulation and markedly prevents early atherogenesis in apolipoprotein E-deficient mice.
    Murayama T; Yokode M; Horiuchi H; Yoshida H; Sano H; Kita T
    Atherosclerosis; 2000 Dec; 153(2):295-302. PubMed ID: 11164418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100.
    Véniant MM; Sullivan MA; Kim SK; Ambroziak P; Chu A; Wilson MD; Hellerstein MK; Rudel LL; Walzem RL; Young SG
    J Clin Invest; 2000 Dec; 106(12):1501-10. PubMed ID: 11120757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both.
    Ishibashi S; Perrey S; Chen Z; Osuga Ji; Shimada M; Ohashi K; Harada K; Yazaki Y; Yamada N
    J Biol Chem; 1996 Sep; 271(37):22422-7. PubMed ID: 8798405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of an oral astaxanthin prodrug (CDX-085) on lipoprotein levels and progression of atherosclerosis in LDLR(-/-) and ApoE(-/-) mice.
    Ryu SK; King TJ; Fujioka K; Pattison J; Pashkow FJ; Tsimikas S
    Atherosclerosis; 2012 May; 222(1):99-105. PubMed ID: 22406426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular localization and metabolism of chylomicron remnants in the livers of low density lipoprotein receptor-deficient mice and apoE-deficient mice. Evidence for slow metabolism via an alternative apoE-dependent pathway.
    Mortimer BC; Beveridge DJ; Martins IJ; Redgrave TG
    J Biol Chem; 1995 Dec; 270(48):28767-76. PubMed ID: 7499399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-mediated gene transfer of human lipoprotein lipase ameliorates the hyperlipidemias associated with apolipoprotein E and LDL receptor deficiencies in mice.
    Zsigmond E; Kobayashi K; Tzung KW; Li L; Fuke Y; Chan L
    Hum Gene Ther; 1997 Nov; 8(16):1921-33. PubMed ID: 9382958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective VLDL metabolism and severe atherosclerosis in mice expressing human apolipoprotein E isoforms but lacking the LDL receptor.
    Knouff C; Briand O; Lestavel S; Clavey V; Altenburg M; Maeda N
    Biochim Biophys Acta; 2004 Aug; 1684(1-3):8-17. PubMed ID: 15450205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cafestol increases serum cholesterol levels in apolipoprotein E*3-Leiden transgenic mice by suppression of bile acid synthesis.
    Post SM; de Roos B; Vermeulen M; Afman L; Jong MC; Dahlmans VE; Havekes LM; Stellaard F; Katan MB; Princen HM
    Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1551-6. PubMed ID: 10845871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid initial removal of chylomicron remnants by the mouse liver does not require hepatically localized apolipoprotein E.
    Yu KC; Jiang Y; Chen W; Cooper AD
    J Lipid Res; 2000 Nov; 41(11):1715-27. PubMed ID: 11060341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a).
    Sanan DA; Newland DL; Tao R; Marcovina S; Wang J; Mooser V; Hammer RE; Hobbs HH
    Proc Natl Acad Sci U S A; 1998 Apr; 95(8):4544-9. PubMed ID: 9539774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive androstane receptor activation decreases plasma apolipoprotein B-containing lipoproteins and atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Sberna AL; Assem M; Xiao R; Ayers S; Gautier T; Guiu B; Deckert V; Chevriaux A; Grober J; Le Guern N; Pais de Barros JP; Moore DD; Lagrost L; Masson D
    Arterioscler Thromb Vasc Biol; 2011 Oct; 31(10):2232-9. PubMed ID: 21778422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum amyloid A and lipoprotein retention in murine models of atherosclerosis.
    O'Brien KD; McDonald TO; Kunjathoor V; Eng K; Knopp EA; Lewis K; Lopez R; Kirk EA; Chait A; Wight TN; deBeer FC; LeBoeuf RC
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):785-90. PubMed ID: 15692094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harmful effects of increased LDLR expression in mice with human APOE*4 but not APOE*3.
    Malloy SI; Altenburg MK; Knouff C; Lanningham-Foster L; Parks JS; Maeda N
    Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):91-7. PubMed ID: 12969990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2.
    Huang Y; Rall SC; Mahley RW
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2817-24. PubMed ID: 9409260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo contribution of LCAT to apolipoprotein B lipoprotein cholesteryl esters in LDL receptor and apolipoprotein E knockout mice.
    Furbee JW; Francone O; Parks JS
    J Lipid Res; 2002 Mar; 43(3):428-37. PubMed ID: 11893779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic low-density lipoprotein receptor-related protein deficiency in mice increases atherosclerosis independent of plasma cholesterol.
    Espirito Santo SM; Pires NM; Boesten LS; Gerritsen G; Bovenschen N; van Dijk KW; Jukema JW; Princen HM; Bensadoun A; Li WP; Herz J; Havekes LM; van Vlijmen BJ
    Blood; 2004 May; 103(10):3777-82. PubMed ID: 14739216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.